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Aggregation and fibril formation of amyloid- (A) peptides
A40 andA42 are central events in the pathogenesis ofAlzhei-
mer disease. Previous studies have established the ratio of A40
to A42 as an important factor in determining the fibrillogen-
esis, toxicity, and pathological distribution of A. To better
understand the molecular basis underlying the pathologic con-
sequences associated with alterations in the ratio of A40 to
A42, we probed the concentration- and ratio-dependent inter-
actions betweenwell defined states of the two peptides at differ-
ent stages of aggregation along the amyloid formation pathway.
We report thatmonomeric A40 alters the kinetic stability, sol-
ubility, and morphological properties of A42 aggregates and
prevents their conversion into mature fibrils. A40, at approxi-
mately equimolar ratios (A40/A42 0.5–1), inhibits (>50%)
fibril formation bymonomericA42, whereas inhibition of pro-
tofibrillarA42 fibrillogenesis is achieved at lower, substoichio-
metric ratios (A40/A42 0.1). The inhibitory effect of A40
onA42 fibrillogenesis is reversed by the introduction of excess
A42 monomer. Additionally, monomeric A42 and A40 are
constantly recycled and compete for binding to the ends of pro-
tofibrillar and fibrillar A aggregates. Whereas the fibrillogen-
esis of both monomeric species can be seeded by fibrils com-
posed of either peptide, A42 protofibrils selectively seed the
fibrillogenesis of monomeric A42 but not monomeric A40.
Finally, we also show that the amyloidogenic propensities of dif-
ferent individual andmixedA species correlates with their rel-
ative neuronal toxicities. These findings, which highlight spe-
cific points in the amyloid peptide equilibrium that are highly
sensitive to the ratio of A40 to A42, carry important implica-
tions for the pathogenesis and current therapeutic strategies of
Alzheimer disease.
Alzheimer disease is a progressive neurodegenerative disor-
der characterized by age-related accumulation of amyloid-
(A)2 proteins in the form of diffuse and neuritic plaques in
regions of the brain that are affected by the disease (1–4). The
discovery of A fibrils as principal constituents of amyloid
plaques led to the emergence of the amyloid hypothesis, which
implicates the aggregation of A as the primary trigger for a
cascade of pathogenic events culminating in neurodegenera-
tion and development of AD (1, 5–7). A proteins are produced
in neuronal and non-neuronal cells as a result of sequential
proteolytic cleavage of the type I transmembrane amyloid pre-
cursor protein (APP) by- and -secretases (8–12). Depending
on the site of APP cleavage by -secretase, A proteins of var-
ious chain lengths are generated (13–16). The predominant A
species in human plasma and CSF, as well as in conditioned
media of APP-expressing cells, is A40 (90%) followed by
A42 (10%). Despite the preponderance of A40, in vivo
studies reveal that A42 is a major constituent of amyloid
plaques and suggest that A42 aggregation plays a critical role
in the initiation of plaque formation and AD pathogenesis (17–
20). In vitro, A42 exhibits lower solubility and has the propen-
sity to form protofibrils and fibrillar aggregates at lower con-
centrations and higher rates than A40 or other A variants
(21–23). A42 aggregates (protofibrils and fibrils) have also
been reported to be more toxic to cultured neurons than A40
aggregates (24, 25).
Although the majority of late-onset AD cases occur sporad-
ically, geneticmutations inAPP or subunits of -secretase (pre-
senilins PS1 or PS2) account for a significant proportion of ear-
ly-onset familial AD (FAD) cases (26, 27). Animalmodels and in
vitro cell culture studies have shown that, in most instances,
FAD mutations enhance total A production, promote its
aggregation and brain deposition, and/or alter the A40/A42
ratio in favor of A42 production (28–30). Recent studies in
human subjects also highlight the importance of A40/A42
ratio, rather than the total concentration ofA, as an important
biomarker for AD progression and disease severity (31–33). To
evaluate the consequences of altering the ratio A40/A42,
several groups have investigated the effect of co-expressing the
two A variants (A40 and A42) or altering the expression
level of one or the other variant in cellular and animalmodels of
AD. These studies and other studies in human patients demon-
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strate that the ratio of A40 to A42 is an important determi-
nant of the distribution of amyloid pathology (i.e. parenchymal
or vascular amyloid deposition) in the brains of patients with
AD and transgenic AD mouse models (18, 34–37).
The molecular mechanisms by which changes in the A40/
A42 ratio modulate the aggregation and toxicity of A and
influence the amyloid pathology distribution in the AD brain
remain the subjects of considerable debate. A40 inhibits fibril
formation by A42 (22, 38), and co-incubation of the two A
variants leads to formation of mixed prefibrillar aggregates in
vitro (39). A40 prevents A42-induced neurotoxicity in cul-
tured cells and in vivo (40), underscoring the regulatory
effects of A40/A42 ratio on important events associated
with A aggregation and toxicity. More recently, Yan and
Wang (41) used differential NMR isotope labeling to dem-
onstrate that A40 prevents aggregation of monomeric
A42 and is capable of being exchanged for A42 monomer
in A42 aggregates.
In the present study, we determined the preferential effect of
A40 on the kinetic stability, solubility, and fibrillogenesis rate
of specific aggregation states of A42, including monomers,
protofibrils, and fibrils. Additionally, we explored the dynamics
of exchange between monomeric A40 and A42 at the end of
protofibrils and fibrils formed by each peptide and determined
the effect of these interactions on the aggregate growth and
morphology in vitro. Finally, we examined the ability of A42
fibrils and protofibrils to seed the aggregation of A40 and vice
versa bymonitoring the seeding effects of homologous and het-
erologous sequence on the lag phase, elongation phase, and
steady-state phase of fibril formation of monomeric A40 and
A42. The specificity of interaction between A40 and differ-
ent A42 aggregation states was validated by using A40-1
(reverse) as a control peptide. The present work provides novel
mechanistic and structural insights into the molecular mecha-
nisms underlying the consequences associated with altered
A40/A42 ratio. The implications of these findings for inter-
vention strategies for AD are also discussed.
EXPERIMENTAL PROCEDURES
Chemicals and reagents of analytical grade were purchased
from Sigma-Aldrich unless indicated otherwise. Best quality
distilled water was used for preparation of buffers and solu-
tions, which were filtered through 0.65-mDVPP membranes
(Millipore) before use.
Preparation of Protofibrillar andMonomeric A
A peptides 1-40, 1-42, and 40-1 were synthesized and puri-
fied by Dr. James I. Elliott at Yale University (New Haven, CT).
Protofibrillar (PF) and monomeric (M) forms of A were pre-
pared according to the protocols described previously (42).
Briefly, A peptides were dissolved in 100% DMSO and
adjusted to 1 mg/ml by adding distilled H2O. The pH of the
resultant solutions was adjusted with 2 M Tris base, pH 7.4.
After centrifugation (8000 g at 4 °C for 10 min) the superna-
tant was injected into a size exclusion chromatography column
Superdex 75 HR 10/30 (GE Healthcare) that had been equili-
brated previously with 10 mM Tris-HCl, pH 7.4. Peptides were
fractionated at a flow rate of 0.5 ml/min and eluted in 1.5-col-
umn volumes. A elution was monitored by UVabsorbance at
three different wavelengths: 210, 254, and 280 nm. Under these
conditions, A42 eluted as two well separated peaks; one cor-
responding to the void volume of Superdex 75 containing A
protofibrils (A42PF) and the second peak corresponding to
monomeric A (A42M) (supplemental Fig. 1). A40 and
A40-1 elute predominantly as single peaks corresponding to
monomeric species (data not shown). The protein concentra-
tions of the various A fractions was estimated by UV absorb-
ance at 280 nm in 10-mm path-length cuvettes using the theo-
retical molar extinction coefficient at 280 nm (1490 M1 cm1)
(43) and/or using the Micro BCA protein assay (Pierce) when
needed.
Fibrillogenesis Studies
Co-incubation of Monomeric A40 with Protofibrillar or
Monomeric A42—Monomeric and protofibrillar preparations
of A42 and A40 obtained by size exclusion chromatography
(SEC) were adjusted to a final concentration of 10–20 M in 10
mM Tris-HCl, pH 7.4, and placed in a 37 °C incubator without
agitation. For co-incubation studies, protofibrillar and mono-
meric A42 fractions were mixed with monomeric A40 at
molar ratios (A42M:A40M) of 10:1, 10:5, and 10:10 (all con-
centrations in M) and allowed to aggregate at 37 °C without
agitation. Fibril formation and protein solubility were moni-
tored by thioflavin T (ThT) binding assay, negative staining
transmission electronmicroscopy (TEM), and analytical SECas
described below. In parallel, the specificity of A40 interactions
withA42was validated by co-incubationwith the control pep-
tide A40-1.
Fibril Elongation Studies—To probe the effect of monomeric
A on the elongation and reassociation of A42 fibrils, we first
generated A42 fibrils by incubating 10 M monomeric A42
(A42M) for 96 h. The fibrils were mechanically fragmented
into smaller fibrillar structures (100–300 nm long) by ultra-
sonication on ice using a Vibra CellTM instrument (Sonics Inc.)
equipped with a 2-mm diameter microtip (20  5 s pulses;
amplitude, 40%; output, 6watts). The sonicated fibrils (A42SF)
were incubated: (i) in isolation; (ii) with monomeric A42 (10
M); (iii) with monomeric A40 (10 M); or (iv) with a 1:1 mix-
ture of monomeric A42:40 (20 M final A concentration).
Fibril elongation and reformation of mature A fibrils was
monitored by ThT fluorescence and TEM.
Seeding Polymerization Studies
Seeding the Fibrillogenesis of Monomeric A (A40 and
A42) with Fibrils Derived fromA40 andA42—Toprobe the
ability of A42 fibrils to accelerate the fibrillogenesis of mono-
meric A40 and vice versa, 20 M monomeric A (A42 or
A40) was incubated with the following: (i) 10g/ml sonicated
A42 fibrils (A42SF, once); (ii) 20g/ml sonicatedA42 fibrils
(A42SF, twice); (iii) 10 g/ml sonicated A40 fibrils (A40SF,
once); and (iv) 20g/ml sonicated A40 fibrils (A40SF, twice).
The extent of fibril formation was determined by ThT fluores-
cence and TEM. ThT fluorescence data were normalized by
subtracting the contribution from sonicated fibrils.
Effect of A40 on Fibrillization of A42
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Seeding the Fibrillogenesis of Monomeric A (A40 and
A42) with A42 Protofibrils—20Mmonomeric A (A40 or
A42) was co-incubated with different molar ratios of protofi-
brillar A42 (monomeric A:A42PF; 20:1, 20:2 and 20:4; all
final concentrations inM) and fibril formation was monitored
by ThT fluorescence after subtracting the contribution from
protofibrillar A42. To probe the specificity of interactions
between the monomeric and aggregated forms of A42 and
A40, we also evaluated the capacity of sonicated fibrils and
protofibrillar species of both peptides (A40 and A42) to seed
the fibrillogenesis of A40-1 (20 M) in a similar fashion.
Thioflavin T Binding Assay
ThT binding assay was performed by mixing aliquots of
10–20 M A with 10–20 M ThT dye (A:ThT 1:1) and 50
mM glycine-NaOH, pH 8.5, in Nunc 384-well fluorescence
plates (Fisher Scientific). ThT fluorescence of each sample was
measured in anAnalyst AD fluorometer (Molecular Devices) at
excitation and emission wavelengths of 450 and 485 nm,
respectively. The samples were analyzed in duplicates at
selected time points.
Transmission ElectronMicroscopy
5 l of sample was applied to carbon-coated Formvar 200
mesh grids (Electron Microscopy Sciences) and incubated at
room temperature for 60 s. The gridswere thenwashed sequen-
tially by depositing 10-l droplets of double distilled sterile
water (2 times) followed by a 10-l droplet of fresh 2% (w/v)
uranyl acetate, which remained on the grid for 30 s. After each
step, the excess solution was blotted with Whatman filter
paper, and the grids were vacuum-dried from the edges. The
samples were analyzed using a Philips CM-10TEMmicroscope
operated at 100 kV acceleration voltage.
Analytical Size Exclusion Chromatography
Analytical SEC was performed to quantify the relative
amount of soluble (monomeric and protofibrillar) A in solu-
tion at selected time points during the aggregation experi-
ments. For this purpose a SEC column Superdex 75 PC 3.2/30
(GEHealthcare) was connected to aWaters SeparationModule
2795 equipped with a photo diode array detector (Waters
Corp.). Aliquots (150 l) of the samples were centrifuged
(8500  g at 4 °C for 10 min), and 50 l of supernatant was
injected into the column. Samples were individually analyzed
byUV absorbance (wavelengths 210, 254, and 280 nm) at a flow
rate of 0.05 ml/min.
Cell Culture Toxicity Studies
Primary Cell Cultures—Rat embryonic (E16) cortical cul-
tures were established using a previously described procedure
(44). Briefly, neurons were plated at a density of 30,000 cells/
well in 96-well dishes (CostarTM, Corning) previously coated
with poly-L-lysine (Mr 30000–70000). On in vitro day 4,
half of the medium was replaced with freshly prepared Neuro-
basalTM medium supplemented with 2% B27 (Invitrogen), 1
penicillin-streptomycin (Invitrogen), 0.5 mM L-glutamine, and
15 mM KCl. Subsequently, half of the medium was changed
weekly. On in vitro day 23, half of the primary culture medium
was replaced with complete Neurobasal medium containing
one-fifth or one-tenth volume of amyloid peptide species with
varying concentrations of A40M, A42M, A42PF, and A42F
and 1:1 molar mixtures thereof. Cells were subsequently incu-
bated with A species for 7 days. All amyloid peptide species
were delivered in 140 mM NaCl, 10 mM Tris, pH 7.4.
Immunostaining—Cell cultures were washed with PBS and
fixedwith 4% paraformaldehyde (Fluka) for 15min at 4 °C. Cul-
tures were subsequently washed with PBS and then incubated
for 1 h in a blocking solution of PBS supplemented with 10%
normal goat serum (DakoCytomation) and 0.1% Triton X-100
in PBS. The cells were then incubated overnight at 4 °C in
blocking solution containing mouse monoclonal anti-NeuN
antibody (1/400, Chemicon Inc.). The next day, cells were
washed and incubated for 2 hwith a fluorescent secondary anti-
body (Cy3-conjugated goat anti-mouse; 1:1,000; Jackson
ImmunoResearch Laboratories) followed by PBS washes.
Immunostained cells were then analyzed with a BD Pathway
855 Bioimager (BD Biosciences). Images for quantitative anal-
yses were acquired under nonsaturating exposure conditions,
and image analysis was performed with NIH ImageJ software.
RESULTS
Isolation and Characterization of Protofibrillar and Mono-
meric A—TEM images of protofibrillar A42 (A42PF) frac-
tions revealed predominantly curvilinear structures with an
average length and diameter of 60–100 and 4–6 nm, respec-
tively (supplemental Fig. 1B). In addition, spherical aggregates
of different diameters (6–10 nm) were also observed occasion-
ally. The second elution peak corresponding to monomeric
A42 (A42M) did not show the presence of any recognizable
aggregates by TEM (supplemental Fig. 1D). 10–20 M concen-
trations of protofibrillar and monomeric A42 species con-
verted readily into fibrils upon incubation at 37 °C (supplemen-
tal Fig. 1, C and E). After 96 h of incubation, almost all A42M
had aggregated into a network of long intertwining fibrils (sup-
plemental Fig. 1E), whereas significant amounts of A42 pro-
tofibrils persisted and coexisted with fibrils under identical
conditions (supplemental Fig. 1C). Unlike A42, A40 and
A40-1 (reverse) eluted predominantly as a single monomeric
peak under the same solubilization conditions (data not shown)
and did not form fibrils under the conditions used for A42
fibrillogenesis studies (supplemental Fig. 2, A, C, and E). Fibril
formation bymonomeric A40 (A40M) required gentle agita-
tion (300 rpm) and higher concentrations (supplemental Fig. 2,
B, D, and F).
Monomeric A40 Inhibits the Fibrillogenesis of Monomeric
A42 in a Concentration-dependent Manner—To probe the
effects of monomeric A40 interactions on the self-assembly
and fibril formation of monomeric A42, we co-incubated
SEC-isolated A42M with increasing concentrations of A40M
(see “Experimental Procedures”). We found that A40M inhib-
ited the fibrillogenesis of A42M in a concentration-dependent
manner. After co-incubation for 96 h, strong (50%) inhibition
of monomeric A42M fibrillogenesis was observed in samples
containing both peptides at A40M/A42M ratios 0.5–1 (Fig.
1A). However, the presence of A40M, even at lower concen-
trations (A40M:A42M 0.1) led to a transient population of
Effect of A40 on Fibrillization of A42
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protofibrillar species (Fig. 1B), which disappeared subse-
quently. In the absence of A40, A42M aggregated rapidly and
formed long intertwining fibrillar networks without the accu-
mulation of protofibrils (supplemental Fig. 1E). In contrast, co-
incubation with A40M favored the formation of short, flexible
protofibrillar structures (Fig. 1, C andD, and Scheme 1), which
did not appear to convert to mature elongated fibrils. Our data
suggest thatA40M interfereswith the ability ofA42M to form
mature fibrils but does not interfere with its ability to form
higher order prefibrillar aggregates. Under no conditions did
we observe that mixtures of monomeric A40 and A42
remained as stable monomers or formed stable heterodimers
on the time scale of our experiments (24–96 h).
Kinetic Stabilization of A42 Protofibrils by Monomeric
A40—Next, we probed the interactions of monomeric A
(A40 and A42) with protofibrillar A42 and assessed the
consequences of such interactions on the elongationA42 pro-
tofibrils into mature fibrils. For this purpose, we co-incubated
A42PF with monomeric A (A40M or A42M) at different
molar ratios (APF:AM, 10:1, 10:5, and 10:10; all final concen-
trations in M) (Scheme 2). The addition of A42M to A42PF
at increasing molar ratios resulted in enhanced ThT binding
(Fig. 2A), consistent with the accelerated conversion of A42PF
FIGURE 1.Monomeric A40 inhibits fibril formation bymonomeric A42
in a ratio-dependentmanner andaffects the structure of amyloid aggre-
gates. A, co-incubation of monomeric A42 with increasing molar ratios
(A42M:A40M, 10:1, 10:5, and 10:10; all final concentrations inM) of mono-
meric A40 results in reduced ThT binding as an inverse function of mono-
meric A40 concentration. The error bars represent mean S.D. in duplicate
samples.M, monomeric A; a.u., arbitrary units. B, SEC analysis on a Superdex
75 PC 3.2/30 column showing that soluble A is transiently detected around
24 h of co-incubation and disappears subsequently, suggesting the forma-
tion of high molecular weight aggregates. Interestingly, co-incubation of
monomeric A42 with monomeric A40 results in formation of various
aggregatemorphologies including short filamentous andprotofibrillar struc-
tures. C and D, TEM images are shown for 10Mmonomeric A42 incubated
at 37 °C with 1 M (C) and 10 M monomer A40 (D). Scale bar 200 nm.
SCHEME 1.Monomeric A40 inhibits the ability of A42 to formmature
amyloid fibrils. The arrows represent the relative concentration of each
species.
SCHEME 2.MonomericA40 inhibits the conversionofA42 intomature
amyloid fibrils and favors the formationof curvilinearprefibrillar aggre-
gates. The arrows represent the relative concentration of each species.
Effect of A40 on Fibrillization of A42
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intomature fibrillar structures (Fig. 2E). SEC analysis after 48 h
of co-incubation revealed that the majority of monomeric and
protofibrillar A42 were converted into insoluble aggregates
and were no longer detectable in solution supernatant after
centrifugation (Fig. 2C). Interestingly, the effect of A40M co-
incubation on inhibition of A42PF fibrillar conversion was
independent of ratio. In the presence of A40M, ThT fluores-
cence of A42PF remained virtually unchanged even after co-
incubation for 96 h (Fig. 2B). To determine whether the lack of
a rise in ThT fluorescence was due to stabilization of A42PF or
formation of lowThT-bindingA aggregates, samples contain-
ing mixtures of A42PF and A40M were subjected to further
analyses by SEC and TEM. When purified A42PF were rein-
jected into an analytical Superdex 75 PC3.2/30 SEC column,we
consistently observed two peaks corresponding to A42PF and
A42M. This may have happened because A42PF are in rapid
equilibrium with monomers and/or
a population of the A42PF is more
susceptible to dissociation upon
interaction with the columnmatrix.
After 24 h of co-incubation in the
presence of 1 M A40M, we
observed a disappearance of the
monomeric peak (Fig. 2D, 25 min),
whereas the intensity and area of the
protofibril peak increased (Fig. 2D,
18 min). Upon further incubation,
the intensity and area of the proto-
fibril peak was markedly reduced
and exhibited a slight shift to higher
molecular weight elution (16 min).
These results suggest that the pres-
ence ofA40Mblocks the formation
of mature A42 fibrils but does not
interfere with the growth of A42
protofibrils and/or possibly leads to
the formation of mixed A40/A42
protofibrillar aggregates. This
hypothesis was confirmed by TEM
studies that revealed protofibrillar
clusters with a predominantly cur-
vilinear morphology for all samples
containing mixtures of A42PF and
A40M regardless of the peptide
ratios (Fig. 2F). The average length
of these aggregates was variable and
significantly larger than that of SEC-
isolated A42PF (supplemental Fig.
1B). Of particular note,mature fibril
structures similar to those formed
by A42 alone (Fig. 2E and supple-
mental Fig. 1E) were scarcely
observed in samples containing
mixtures of A42PF and A40M.
Lack of Effect of A40-1 onMono-
meric or Protofibrillar A42 Fibril-
logenesis—To validate the specific-
ity of the inhibitory effect of A40
on the fibrillogenesis ofmonomeric and protofibrillar A42, we
co-incubated A42PF or A42M with A40-1 at varying molar
ratios (A42:A40-1, 10:1, 10:5, and 10:10; all final concentra-
tions inM). The results of these studies show thatA40-1 does
not inhibit fibril formation by protofibrillar A42 at any of the
concentrations tested (supplemental Fig. 3A). However,
A40-1 had a small inhibitory effect on A42M fibrillogenesis
at a 1:1 ratio (supplemental Fig. 3B), but this activity was much
less pronounced than the inhibitory affect of A40M (Fig. 1A).
These results underscore the specificity of the interactions
between the two endogenous A variants (A40 and A42)
during amyloid fibril formation.
Monomeric A40 Interferes with Growth and Reassembly of
Preformed A42 Fibrils—Whereas the above findings indicate
that A40 inhibits de novo fibrillogenesis of monomeric and
protofibrillar A42, we next sought to explore the possible
FIGURE 2.Monomeric A40 imparts kinetic stability to protofibrillar A42 and retards protofibril to fibril
conversion. The addition ofmonomeric A42 to A42 protofibrils accelerates fibril formation (A), whereasmono-
meric A40 disfavors fibril formation by protofibrillar A42 at identical molar ratios (B) (A42PF:A40M, 10:1, 10:5,
and 10:10; all final concentrations inM). SEC analysis on a Superdex 75 PC3.2/30 column revealed that addition of
monomeric A42 to A42 protofibrils results in diminished solubility (C) and formation of extensive fibrillar net-
works (E). In contrast, monomeric A40 promotes solubility of protofibrils over the time of co-incubation (D) and
retardsconversionofprotofibrils intoelongated fibrils (F).Scalebar200nm.Theerrorbars inAandB represent the
mean S.D. in duplicate samples.M, monomeric A; PF, protofibrillar A42; a.u., arbitrary units.
Effect of A40 on Fibrillization of A42
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effect of A40 on the growth and assembly of preexisting A42
fibrils. A42 fibrils were mechanically disrupted by ultra-soni-
cation to generate a narrowdistribution of small, 100–300-nm-
long fibrillar structures with an average diameter of 10 to 12 nm
(Fig. 3, B and C). The sonicated A42 fibrils (A42SF) were
allowed to reassociate at 37 °C as follows: (i) in isolation; (ii) in
the presence of A42M (10 M); (iii) in the presence of A40M
(10 M); or (iv) in the presence of a 1:1 mixture of A42M and
A40M (20M final A concentration) (Scheme 3). Upon incu-
bation for 72 h at 37 °C, the fragmented A42 fibrils reassoci-
ated to form elongated fibrils with morphological features sim-
ilar to the parent fibrils (data not shown). The addition of
A42M to fragmented fibrils accelerated fibril growth and led to
the emergence of mature fibrillar structures (Fig. 3, A and D),
whereas the addition of A40M retarded their growth and
blocked fibril reassembly as evidenced by significantly reduced
ThT fluorescence (Fig. 3A). TEM images of the fragmented
fibrils incubated in the presence of A40M also revealed pre-
dominantly truncated fibrillar aggregates and the absence of
mature fibrils (Fig. 3E). Co-incubation of sonicatedA42 fibrils
with a 1:1 mixture of A42M:A40M resulted in fibril growth
and reassembly but to a lesser extent than seen after A42M
addition (data not shown). These observations suggest that
A40, at near equimolar ratios, retards the elongation andmat-
uration of fragmented A42 fibrils into classical ThT-binding
amyloid fibrils (as shown in Figs. 2E and 3B and supplemental
Fig. 1E).
Monomeric A42 and A40 Are Constantly Recycled and
Compete for Binding to the Ends of Protofibrillar and Fibrillar
A Aggregates—The above observations highlight a significant
degree of molecular cross-talk between A40 and different
aggregation states of A42 (monomer, protofibrils, and fibrils)
during amyloid fibril formation. Hence, we ventured to further
explore this phenomenon and probe the dynamics of exchange
betweenmonomericA42 andA40 at the endof protofibrillar
and fibrillar forms of A42. For this purpose, A42 protofibrils
(10 M) were incubated in presence of A42M (10 M), A40M
(10 M), or a 1:1 mixture of both peptides (20 M final A
concentration) for 72 h (Fig. 9). After this, a second 10 M
addition of freshly prepared monomeric A species (A42M,
A40M, or A42M plus A40M) was carried out, and the result-
ant mixtures were incubated for an additional 78 h (150 h total)
(Scheme 4). At each step of the process, the presence of fibrils
was monitored by ThT binding and negative staining TEM. As
expected, the addition of A42M to A42PF resulted in
enhancedThT fluorescence (Fig. 4A, II, 72 h) and the formation
FIGURE 3. Monomeric A40 interferes with A42 fibril reorganization
and elongation at an equivalent ratio. Fibrillar A42 (B) was sonicated to
generate fragmented fibrils (C), which were incubated at 37 °C for 72 h (A) in
isolation (white bar), with 10Mmonomeric A42 (light gray dotted bar), with
10 M monomeric A40 (dark gray dotted bar), and with a 1:1 mixture of the
latter two (oblique striped bar). The addition ofmonomeric A42 results in the
resumption of fibril elongation (D), whereas the addition ofmonomeric A40
at a 1:1molar ratio to sonicated A42 fibrils delays A42 fibril elongation and
maturation (E). Scale bar 200 nm. The error bars in A represent the mean
S.D. in duplicate samples. M, monomeric A; F, fibrillar A42; SF, sonicated
A42 fibrils; a.u., arbitrary units.
SCHEME 3. Monomeric A40 interferes with growth and reassembly of
preformed A42 fibrils. The arrows represent the relative concentration of
each species.
SCHEME 4.Monomeric A42 and A40 compete for binding to the ends
of protofibrillar and fibrillar A.
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of dense fibrillar networks (Fig. 4B). Interestingly, whenA40M
was added to this fibrillized A42 and incubated for an addi-
tional 78 h, ThT fluorescence was substantially reduced (Fig.
4A, II, 150 h), and in addition to fibrils, a substantial amount of
curvilinear, non-fibrillar structures were also observed (Fig.
4C). In contrast, when A42PF were co-incubated with A40M
for 72 h, therewas a negligible rise inThT fluorescence (Fig. 4A,
III, 72 h), and non-fibrillar structures resembling protofibrils
were observed as the predominant species (Fig. 4D). However,
the addition of A42M overcame the stabilizing effect of A40
on protofibrils, resulted in enhancedThT fluorescence (Fig. 4A,
III, 150 h), and led to emergence of longmature fibrils (Fig. 4E).
Finally, serial additions of a 1:1 mixture of monomeric A42M:
A40M to A42 protofibrils resulted in a slight rise in ThT
fluorescence relative to that obtained upon the addition of
A40M alone (Fig. 4A, IV). An examination of this sample by
TEM revealed mainly curvilinear non-fibrillar structures and
short protofibrils (Fig. 4, F andG). The observation that A40M
can alter the structure of preformedA42F supports the notion
that A40 and A42 monomers are exchangeable at the grow-
ing ends of amyloid aggregates (protofibrils and fibrils).
Seeding Polymerization of Monomeric A (A42 and A40)
with Protofibrillar and Fibrillar A (A42 and A40)—Amy-
loid fibril formation occurs via a nucleation-dependent polym-
erization process akin to protein crystallization (45, 46). Con-
ventionally, a nucleated polymerization process is divisible into
three closely related phases: (i) a slow nucleation “lag” phase
comprising thermodynamically unfavorable interactions of
protein molecules leading to the formation of nuclei (or seeds);
(ii) an elongation phase leading to the emergence of higher
order aggregates (fibrils); and lastly, (iii) a steady-state phase in
which there is a dynamic equilibrium between the fibrils and
monomers in solution (46). The duration of lag phase is signif-
icantly shortened in thepresenceofpreformed“nuclei” or “seeds,”
which promote accelerated self-assembly and amyloid formation
bymonomeric protein (47).This seeding effect has alsobeendem-
onstrated to be a sequence-specific process (48–50).
A42 Fibrils Nucleate the Fibrillogenesis of Monomeric A40
andVice Versa—Previous studies have established the ability of
A fibrils to induce fibril formation bymonomeric A through
the process of nucleated polymerization (22, 38). Thus, we
sought to explore the ability of both well characterized protofi-
brillar and fibrillar forms of A42 to seed the fibrillogenesis of
monomeric A40 and A42. For these experiments, we iso-
lated aggregate-free monomeric A40 and A42 by SEC and
characterized its fibrillogenesis in the presence of different
amounts of fibrillar seeds of either A40 or A42 (sonicated
fibrils of A42SF at 10 and 20 g/ml and sonicated fibrils of
A40SF at 10 and 20 g/ml) (Scheme 5). A42M (20 M) alone
(with no seeds) exhibited an appreciable rise in ThT binding
after 15 h and reached a plateau after 50 h of incubation at 37 °C.
The addition of sonicated fibrils of A42SF abolished the lag
FIGURE4.MonomericA40andA42exchangealongdifferent stagesof
amyloid formation imparts distinct structural features on amyloid
aggregates. A42 protofibrils were exposed to sequential addition of either
monomeric A42 ormonomeric A40 for an extended period of time (A) (see
“Experimental Procedures” and Fig. 8 for details). When added to A42 fibrils,
monomeric A40 alters the fibrillar structure (B) and leads to the emergence
of curvilinear morphologies (C). Moreover, the addition of monomeric A42
to A40-stabilized protofibrils (D) results in conversion of protofibrillar struc-
tures into elongated fibrils (E).When added toA42protofibrils, a 1:1mixture
of monomeric A42 and A40, delays the emergence of mature fibrils (72 h
(F) and150h (G)).Scale bar200nm.The error bars inA represent themean
S.D. in duplicate samples.M, monomeric A; PF, protofibrillar A42; a.u., arbi-
trary units.
SCHEME 5. A42 fibrils nucleate the fibrillogenesis of monomeric A40
and vice versa.
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phase and reduced the time required to reach near equilibrium
levels of fibril formation (9–15 h) (Fig. 5A). Interestingly,
addition of sonicated fibrils of A40SF also decreased lag phase
time but exhibited a longer time to reach near equilibrium
(25–30 h) (Fig. 5A). Regardless of the seeding species, A42M
forms similar fibrils that are1m long and have diameters of
10–14 nm. These fibrils appear to be composed of 2–3 proto-
filaments and exhibit a helical twist spaced at 60–180 nm (Fig.
5, E and F). For the purpose of discussion, we will refer to these
fibrils as type I A fibrils.
In parallel, we investigated the ability of A40SF and A42SF
to seed the fibrillogenesis of monomeric A40. For this pur-
pose, A40M (20M)was co-incubatedwith A42SF (10 and 20
g/ml) and A40SF (10 and 20 g/ml). It is noteworthy that
FIGURE 5. A (A40 and A42) fibrils induce polymerization of monomeric A (A40 and A42), and the structure of resultant amyloid fibrils is
determinedbymonomericA. Fibril formationby 20Mmonomeric A (A40M andA42M)was inducedby twodifferent concentrations (10 and20g/ml)
of fibrillar A42 (C) or fibrillar A40 (D). The addition of fibrillar A (A40 or A42) to monomeric A42 abolishes the lag phase of fibril formation, and similar
equilibrium levels are achieved regardless of the nature and concentration of fibrillar seeds added (A). In contrast, when monomeric A40 aggregation is
seeded with fibrillar A (A40 or A42), although the lag phase is shortened, steady-state levels depend on the amount of fibrillar seeds added (B). Electron
microscopic imagesofmonomericA42aggregationseededwithfibrillarA42(E)andfibrillarA40(F),alongwithmonomericA40aggregationseededwithfibrillar
A42 (G) and fibrillarA40 (H), reveal that the structureof the resultant amyloid fibrils isdeterminedby themonomericA regardlessof thenatureandconcentration
of fibrillar A added as seeding effectors. Scale bar 200 nm. ThT data were normalized by subtracting the ThT fluorescence values obtained from incubation of
sonicated fibrils (10 and 20g/ml) in isolation.M, monomeric A; SF, sonicated A fibrils; 1 10g/ml; 2 20g/ml; a.u., arbitrary units.
Effect of A40 on Fibrillization of A42
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A40M (20 M) alone (with no seeds), under stagnant condi-
tions, did not form amyloid fibrils during the time scale of these
experiments (Fig. 5B and supplemental Fig. 2, A and E) but
formed fibrils readily at higher concentrations or under agitat-
ing conditions (supplemental Fig. 2, B and F). When A40SF or
A42SF was added to the solution of monomeric A40, we
observed two distinct effects on A40 assembly: (i) the elonga-
tion phase was sensitive to the concentration of seeding fibrils,
and (ii) at all time points, the level of ThT binding near equilib-
rium was relatively higher in the presence of A40SF than of
A42SF, suggesting preferential seeding in the presence of
A40SF (Fig. 5B). Moreover, A40M generated similar fibrils
regardless of the nature and amount of seeding species (Fig. 5,G
andH). The resulting fibrils had variable lengthswith diameters
of 6 to 14 nm. The fibrils formed by of A40 consisted of 3
protofilaments and exhibited a helical periodicity of 110 to 180
nm. TEM analysis of a 20 M A40M sample incubated under
identical conditions for 100 h did not show any fibrils (data not
shown).
A42 Protofibrils Seed the Fibrillogenesis ofMonomeric A42
but NotMonomeric A40—To explore the ability of A42 pro-
tofibrils to seed the fibrillogenesis ofmonomeric A (A40 and
A42), we co-incubated 20 M monomeric A (A40M or
A42M) with three different molar ratios of A42PF (i.e. AM:
A42PF at 20:1, 20:2, and 20:4; all final concentrations in M).
We found that even the lowest concentration of A42PF (1M)
was sufficient to accelerate the fibrillogenesis of monomeric
A42 (Fig. 6A), whereas no such effect was observed (for any
molar ratio) when A42PF were added to monomeric A40
under identical conditions (Fig. 6B). TEM analysis of these co-
incubation samples confirmed the validity of the above men-
tioned observations such that when protofibrillar A42 was
added to monomeric A42, extended networks of fibrillar
structures were observed at all molar ratios (A42M:A42PF,
20:4 M (Fig. 6C)). In contrast, the addition of A42PF to
A40M resulted in the formation of mainly short flexible non-
fibrillar structures (A40M:A42PF, 20:4 M (Fig. 6D)). The
absence of mature A40 fibrils indicates that A42 protofibrils
are less efficient as seeding nuclei for A40 fibrillogenesis as
compared with fibrillar A42.
In parallel, we co-incubated 20 M A40-1 with sonicated
fibrils of A (A40SF or A42SF; 20 g/ml) or protofibrillar
A42PF (4 M) as control experiments. Neither fibrillar A
(A40SF and A42SF) nor protofibrillar A42PF resulted in
fibril formation from A40-1 (supplemental Fig. 5).
Treatment of Cultured Neurons with Specific Aggregation-
proneA Species orMixtures Is AssociatedwithDecreasedNeu-
ronal Viability—Toassess the differential effects ofmonomeric
A (A40 or A42) on the toxicity of A42 aggregates to pri-
FIGURE 6. A42 protofibrils do not serve as efficient seeding nuclei for
A40 fibril formation. Fibril formation by 20 M monomeric A (A40 and
A42) was induced at three different concentrations (1, 2, and 4 M) of
protofibrillar A42. The addition of protofibrillar A42 to monomeric A42
abolishes the lagphaseof fibril formation in a concentration-dependent fash-
ion (A) and promotes fibril formation (C). In contrast, no seeding effect is
observedwhen similar concentrations of protofibrillar A42 are added to the
solution containing monomeric A40 (B), and predominantly curvilinear
structures, reminiscent of protofibrils, are observed (D). Scale bar 200 nm.
ThT data were normalized by subtracting the ThT fluorescence values
obtained from incubation of A42 protofibrils (1, 2, and 4M) in isolation.M,
monomeric A; PF, protofibrillar A42; 1 1 M; 2 2 M; 4 4 M;
a.u., arbitrary units.
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mary cortical neurons, we applied these species to cultured E16
rat cortical neurons. Cell survivalwasmeasured by the numbers
of surviving NeuN-positive cells after 7 days of treatment (see
“Experimental Procedures”). A40M showed no significant
effect on neuronal viability at concentrations between 0.1 and
10M (Fig. 7,A and F, and supplemental Fig. 6), consistent with
its reduced propensity to aggregate and fibrillize in vitro. At
concentrations from 0.1 to 5 M, neither A42M nor A42PF
had an effect on neuronal viability (Fig. 7A and supplemental
Fig. 6). Interestingly, when 5 M monomeric A (A40 or
A42) was mixed with A42PF, only the mixtures containing
A42M resulted in significant loss of neuron viability (n 5 p	
0.002; Fig. 7,A,C, andD). To determinewhether the decrease in
neuronal viability was due to an increase in the total concentra-
tion ofA42, we probed the effect ofmonomeric, protofibrillar,
and fibrillar forms of A42 on neuronal viability at 10 M con-
centration. Both monomeric and
protofibrillar A42, but not A42
fibrils, caused significant reduction
in neuronal viability, with mono-
meric A42 consistently showing a
pronounced effect (A42M: n  5
p 	 105 (Fig. 7, A and E); A42PF:
n  5 p 	 0.01 (Fig. 7, A and G)).
Exposure to a 1:1 mixture of A42M
and A40M (5 M each) had no
effect on neuronal viability (Fig. 7A).
These results support a central role
of A42 in neurotoxicity as well as
the notion that A-mediated cell
death requires ongoing nucleation-
dependent polymerization of A42
(51).
DISCUSSION
Increasing evidence from genet-
ics, clinical, and cell culture studies
suggests that the ratio of A40 to
A42, rather than the total amount
of A, is an important determinant
of A aggregation, fibrillogenesis,
and toxicity (52). However, the
molecular mechanisms by which
changes in this ratio alter the aggre-
gation, clearance, and distribution
ofA in vivo remain uncertain. Sim-
ilar studies reported previously have
examined the effects of single A
species or total A concentrations
(A40 
 A42) but have not ex-
plored the interactions of distinct
A aggregate states (e.g.monomers,
oligomers, protofibrils, and fibrils).
Given that both A42 and A40
peptides exist in equilibrium
between these different states in
vivo, it is crucial to determine how
the interactions between distinct
aggregation states of each peptide influence A aggregation,
fibril formation, and cellular toxicity. In the present work, we
have uncovered new aspects of A aggregation equilibria by
investigating the ratio-dependent effects of monomeric A40
on the fibrillogenesis of monomeric and protofibrillar forms of
A42 and the dynamic reassembly of short A42 fibrils. By
studying well defined aggregation states of A, our findings
provide critical new mechanistic insights about how A40 and
A42 interact at different stages along the amyloid formation
pathway. These findings have allowed us to develop a new
working model of A42 and A40 interactions, which could
serve as mechanistic explanation for in vivo amyloid formation
(Fig. 9).
The Ratio of A42 Aggregates to Monomeric A40 Is an
Important Determinant of A Aggregation and Fibrillogenesis—
The in vitro studies presented here demonstrate that maintain-
FIGURE 7. Conditions favoring accelerated aggregation of A42 in vitro are associated with enhanced
neurotoxicity.Cultured rat E16primary cortical neuronswere treated for 7dayswithA40 (monomeric), A42
(monomeric, protofibrillar, and fibrillar) or 1:1mixtures thereof, as indicated under “Experimental Procedures.”
Cell viability was quantified after immunostaining for the neuronal marker, neuronal nuclei (NeuN). Graphs
represent the means  S.E. of at least five replicates. Treatment with 10 M A42 protofibrils (A and G) caused
significant (t test; *, p	 0.01), butmilder toxicity than 10Mmonomeric A42 (A and E) or amixture ofmonomeric
andprotofibrillarA42(AandC) (5Meach) (t test; *,p	0.002). Incontrast, cellsexposedto10MmonomericA40
(AandF), 10MA42 fibrils (A), oramixtureofmonomericA40andprotofibrillarA42 (5Meach;AandD)didnot
show significant neurotoxicity. Veh, vehicle.
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ing a delicate balance not only between themonomeric forms of
A42 and A40 but also between the monomeric and aggre-
gated forms of both peptides is essential for maintaining A
solubility and preventing A fibrillogenesis and toxicity. First,
in the presence of excess A40M (as is expected under normal
physiological conditions), A42M aggregation is discouraged
because of its low concentration and the inhibitory effect of
excess A40M. As the concentration of A42M increases (due
to FAD-associatedmutations in APP or other local factors), the
formation of highmolecular weight protofibrillar aggregates or
low ThT-binding fibrillar structures is favored (Fig. 8). The
molecular size, kinetic stability, and potential toxicity of such
species depend on the local concentration of A40 at the site of
their formation or localization. The stabilization of protofibril-
lar and/or low ThT-binding A aggregates could explain the
lack of clear correlation between amyloid plaque pathology and
cognitive decline in patients with
AD (53–55). Figs. 8 and 9 summa-
rize the effect of the ratio of mono-
meric (A40 and A42) to aggre-
gated forms of A40 and A42 in
the structural and ThT binding
properties of the resultant A
aggregates. At higher A42M/
A40M ratios, amyloid fibril forma-
tion is favored and can be acceler-
ated by seeding with fibrils of either
A40 or A42. At A40M/A42PF
andA40M/A42F ratios of 0.5 to 1,
the formation of mature amyloid
fibrils is inhibited, and predomi-
nantly protofibrillar and/or low
ThT binding fibrils are formed.
Interestingly, A42 fibrils seed the
fibrillogenesis of both peptides
(A40 and A42); however, A42
protofibrils were found to seed the
fibrillogenesis of monomeric A42
but not of monomeric A40. These
observations support the notion
that A42 is more highly fibrillo-
genic and plays a crucial role in the
initiation and progression of A
aggregation.
A42 Fibril Growth andReassem-
bly Is Modulated by Constant Recy-
cling and Competition between
Monomeric A40 and A42—Pre-
vious studies have shown that amy-
loid fibril growth occurs by mono-
mer addition to the growing fibril
ends (56–59). In addition, NMR
andmass spectrometry studies have
also shown that monomeric sub-
units constantly recycle in and out
of the fibrillar backbone (60, 61).
Given our findings that A40 inhib-
its the fibrillogenesis of monomeric
and protofibrillar A42, we hypothesized that A40 also inter-
venes in the growth and reassembly of A42 fibrils. We envi-
sioned that his could occur by severalmechanisms, two of them
being; (i) by competing at the free ends of A42 fibrils and
preventing addition of monomeric A42; or (ii) by interacting
and sequestering free monomeric A42 in solution and pre-
venting its docking back into A42 fibrils. To test these two
possibilities, we examined the effect of A40 on the growth and
reassembly of fragmented A42 fibrils (see “Experimental Pro-
cedures”). In the presence of excessmonomeric A42, the frag-
mented A42 fibrils grew and reassembled rapidly to form
fibrillar structures identical to that of the parent fibrils (Figs. 3B
and 9). In contrast, the addition of monomeric A40 retarded
A42 fibril reassembly, led to the accumulation of truncated
fibrillar structures that exhibited low ThT binding and did not
convert to mature fibrils in our experimental time scale (up to
FIGURE 8. The ratio ofmonomeric (A40 andA42) to aggregated forms of A40 andA42 is an impor-
tant determinant of A aggregation and fibrillogenesis. This is a schematic illustration of the effect of
monomeric A40M on the fibrillogenesis of themonomeric (A), protofibrillar (B), and fibrillar (C) forms of A42.
A40 and A42 species (M, PF, and F) are depicted in grey and black, respectively. The level of ThT dye binding
and fluorescenceobserved for the final aggregates formed ineachof theexperiments listed is indicatedbyplus
signs:




 is indicative of high ThT fluorescence, and
 is indicative of low ThT fluorescence.
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150 h). Extending this approach further, we carried out sequen-
tial additions of monomeric A42 and monomeric A40 to
different A aggregation states (Fig. 9). The addition of mono-
meric A40 to A42 protofibrils resulted in the formation of
curvilinear, non-fibrillar aggregates (Figs. 4D and 9). However,
upon reintroduction of monomeric A42, these structures dis-
appeared, and mature amyloid fibrils of A42 emerged as the
predominant species (Fig. 4E). These observations provide
experimental support for the recycling and exchange of mono-
meric A42 and monomeric A40 at the growing ends of A
aggregates (protofibrillar and fibrillar). This is consistent with
recent NMR-based reports that A40, when added to the solu-
tion of aggregated A42, is capable of displacing A42 mono-
mers with the latter being recycled into solution (41). Studies
are currently under way to determine quantitatively the rate of
monomer exchange or preferential incorporation of A40 or
A42monomers intoA42 aggregates (protofibrils and fibrils).
The fact that A42 fibrils continue to grow, albeit slowly,
when co-incubated withmonomeric A40 indicates that A40
can dock and self-assemble on the free ends ofA42 fibrils, thus
resulting in the formation of mixed fibrils (Fig. 3, A and E) (56).
This latter observation also suggests that A40 inhibits the for-
mation of mature amyloid fibrils by A42 but does not block
self-assembly into non-fibrillar aggregates (Fig. 9). Further-
more, at A40M/A42M ratios of 0.5 to 1, we observed nearly
complete conversion of monomeric A40 and A42 into high
molecular aggregates over time (Fig. 1B). This latter finding
suggests that A40-mediated inhibition of A42 fibrillogen-
esis is due to its interaction with some oligomeric/aggre-
gated form(s) of A42 rather than to the formation of stable
A heterodimers.
Kinetic Stabilization of A42 Aggregates by A40 May
Underlie Its Effect on A Aggregation, Toxicity, and Pathology
Distribution in Vivo—The transient
formation of protofibrils during the
fibrillogenesis of almost all amyloid
forming proteins supports the
notion that protofibrils are obligate
intermediates that are likely to exist,
at least transiently, in vivo. A pro-
tofibrils and oligomers (dimers, tri-
mers, up to dodecamers) have been
prepared in vitro from synthetic
peptides or purified from condi-
tioned media of APP-overexpress-
ing cells (62, 63), are biologically
active entities (64), and bind, albeit
weakly, to the amyloid-specific dyes
such as ThT and Congo red (65).
Several independent studies have
implicated A protofibrils as the pre-
dominant toxic species through
effects that include inhibition of long
term potentiation (64, 66), disruption
of signal transduction (67), and for-
mation of channels or pores in cellu-
lar membranes (68–70). These find-
ings have led to the hypothesis that
conversion of small toxic A aggregates into fibrils, and their
sequestrationwithin inclusions or plaques, is neuroprotective and
may represent an active natural detoxification mechanism (71).
Hence, it can be argued that factors that alter the distribution
and/or kinetic stability of A protofibrils should influence their
aggregation and toxicity in vivo. Therefore, stabilizing a toxic pop-
ulation of protofibrils should enhance toxicity and accelerate dis-
ease progression. In contrast, stabilization of a nontoxic protofi-
brillar or fibrillar forms ofAmayhave beneficial effects. In fact, a
recent report suggests that reducing the lifetime of protofibrils by
accelerating their conversion into amyloid fibrils protects against
A induced toxicity (72).
Our study demonstrates that A40 enhances the kinetic sta-
bility of A42 protofibrils and, at high concentrations, pro-
motes the formation of low ThT-binding aggregates. This
could provide possible mechanistic explanations for the effect
of the ratio of A40 to A42 on the distribution of amyloid
pathology (parenchymal versus vascular). In the presence of
high A40M/A42F or A42M/A40F ratios (10), A fibril
formation is accelerated and leads to local accumulation of
fibrillar aggregates in brain parenchyma. In contrast, subphysi-
ologic A40M/A42 (monomeric or protofibrillar) ratios
(0.5–2) favor the accumulation and persistence of soluble A
aggregates (protofibrils and other non-fibrillar structures).
Being relatively soluble in nature, such aggregates can be trans-
ported across different brain compartments, including the vas-
culature, where they can fibrillize if encountered by supraphysi-
ologic concentrations of monomeric A42 and A40. This
model supports a critical role for A42 role in initiating and
accelerating A40 fibrillization in the vasculature, as has also
been reported (19, 73).
Fibrillogenesis of A Contributes to A Neurotoxicity—To
establish the neurotoxic activities of individual and mixed A
FIGURE 9. A42 fibril growth and reassembly is modulated by constant recycling and competition
betweenmonomericA40andA42. This is a schematic depiction of the dynamic exchangebetweenA42
andA42monomers at the ends of A42 aggregates and the consequences of such an exchange on the A42
fibrillar morphology and ThT dye binding.
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(A40 and A42) monomers and aggregates, we treated cul-
tured neurons with defined aggregate states of A42 (protofi-
brils and fibrils) with or without the addition of monomeric A
(A40 or A42). Comparative analysis of NeuN positivity
revealed that neither monomeric A (A40 or A42) nor
aggregated A42 (protofibrillar or fibrillar) was sufficient to
impair neuronal viability at lower (0.1 and 5M) concentrations
(Fig. 7A and supplemental Fig. 6). Furthermore, adding mono-
meric A40 to A42 (monomeric, protofibrillar, or fibrillar; 5
M each) did not enhance A toxicity (Fig. 7, A and D). How-
ever, the addition ofmonomeric A42 to protofibrillar A42 (5
M each) or 10 M monomeric A42 significantly impaired
neuronal viability (Fig. 7, A, C, and E), suggesting that perpetu-
ating the aggregation of A42 increases A toxicity. Interest-
ingly, a higher concentration (10 M) of protofibrillar A42 or
preformed A42 fibrils did not show comparable toxicity (Fig.
7, A andG). These data are consistent with a dominant role for
A42 in impairing neuron viability (19, 25) and further impli-
cate the ongoing A self-assembly process (rather than any
specificA aggregation state) inA-associated toxicity (51, 74).
These results also add credence to therapeutic strategies aimed
at disrupting the nucleation or elongation of amyloid fibrils to
inhibit A neurotoxicity in AD.
Conclusions—Potential interactions between A40 and
A42 have been investigated previously by various research
groups. These studies have shown that A40 can inhibit the
aggregation and fibril formation of A42 (38, 41) and protect
cultured neurons fromA-induced neurotoxicity (40). In addi-
tion to confirming the findings of these studies, the present
study serves as a critical contribution to the current under-
standing of A40 and A42 interactions by examining the spe-
cific interplay of biophysically defined A species (and mix-
tures thereof). Unlike previous studies suggesting that A40
blocks the aggregation of monomeric A42 (41), our results
show that A40 does not prevent further aggregation of the
various A42 quaternary structures (monomeric, protofibril-
lar, and fibrillar). Instead, we have demonstrated that A40
alters the kinetic stability, solubility, and morphological prop-
erties of A42 aggregates and prevents the formation ofmature
fibrils. Accordingly, we found that A40 inhibits fibril forma-
tion of monomeric A42 in a concentration-dependent man-
ner (Fig. 1), whereas the effect on protofibril and fibril elonga-
tion is concentration-independent (Fig. 2).We have also shown
that changes induced by A40 are reversible upon reintroduc-
tion of high concentrations of A42. Our results also confirm
previous findings on the seeding capacity of A40 and A42
fibrils (Fig. 5), but to our knowledge this is the first report show-
ing that A42 protofibrils have the capacity to enhance the
fibrillogenesis of A42 but not of A40 (Fig. 6D). Importantly,
we have also begun to establish the relevance of the interactions
of specific A species in vivo. These results suggest that the
continued pursuit of a quantitative and structural understand-
ing of how A40 and A42 interact may eventually provide
better biomarkers and therapies for the treatment of AD.
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